Associated Papers
Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients.
Xie XC et al.
Acta Pharmacologica Sinica, 2015
Association of the CYP2B6 c.516G>T polymorphism with high blood propofol concentrations in women from northern Greece.
Mastrogianni O et al.
Drug Metabolism and Pharmacokinetics, 2014
Genotype and allele frequencies of polymorphic UGT1A9 in the Polish population.
Zakerska O et al.
European Journal of Drug Metabolism and Pharmacokinetics, 2013
Compound heterozygote of a novel missense mutation (p.K402T) and a double missense mutation (p.[G71R;Y486D]) in type II Crigler-Najjar syndrome.
Maruo Y et al.
Journal of Pediatric Gastroenterology and Nutrition, 2011
Genetic polymorphism in metabolism and host defense enzymes: implications for human health risk assessment.
Ginsberg G et al.
Critical Reviews in Toxicology, 2010
Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase (UGT1A9).
Takahashi H et al.
Basic & Clinical Pharmacology & Toxicology, 2008
Interactions with other human UDP-glucuronosyltransferases attenuate the consequences of the Y485D mutation on the activity and substrate affinity of UGT1A6.
Kurkela M et al.
Pharmacogenetics and Genomics, 2007
The interactions between the N-terminal and C-terminal domains of the human UDP-glucuronosyltransferases are partly isoform-specific, and may involve both monomers.
Kurkela M et al.
Biochemical Pharmacology, 2004
Select a paper to view details